Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
filgotinib 200mg/day
DRUG
2 trials
Sponsors
Atsushi Kawakami
, University Hospital, Toulouse
Conditions
Biomarker
IL-6 Inhibitor
JAK Inhibitor
Musculoskeletal Ultrasound
Rheumatoid Arthritis
Rheumatoid Arthritis (RA
Phase 3
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
NCT05090410
Atsushi Kawakami
Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor +2
Start: 2021-03-03
End: 2023-12-31
Target: 400
Updated: 2021-11-01
Phase 4
JAK Inhibitor Dose TAPering Strategy Study
Recruiting
NCT06687551
University Hospital, Toulouse
Rheumatoid Arthritis (RA
Start: 2025-06-06
End: 2029-04-01
Target: 308
Updated: 2026-08-07
Related Papers
Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).
2026-04-27
Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
Trials
2023-03-03
6 citations